

Please join us for this Industry Interactive Discussion at the 36th ECNP Congress

# Management of patients with ADHD and substance use disorders

Product information may occur



Monday, October 09, 2023 | 13:00–13:30 CEST  
Centre Convencions Internacional de Barcelona (CCIB), Room 118

**Josep Antoni Ramos-Quiroga** and **Wim van den Brink** will discuss how we can optimize multimodal treatment for patients with ADHD and SUD as we consider treatment initiation, dose titration, and nonpharmacological and pharmacological treatment follow-up.



**JOSEP ANTONI RAMOS-QUIROGA, MD, PHD**

Professor of Psychiatry at  
Universitat Autònoma de Barcelona, Spain, and  
Head of the Department of Psychiatry at the  
Hospital Universitari Vall d'Hebron, Barcelona, Spain



**WIM VAN DEN BRINK, MD, PHD**


Professor Honoris Causa at the Eötvös Loránd University  
in Budapest, Hungary, and one of the founders and  
President of the International Collaboration of ADHD  
and Substance Abuse (ICASA)

TOPIC	PRESENTER
Welcome (3 mins)	Josep Antoni Ramos-Quiroga
Management of patients with ADHD and SUD (7 mins)	Wim van den Brink
Panel discussion (18 mins)	Josep Antoni Ramos-Quiroga Wim van den Brink
Conclusions (2 mins)	Josep Antoni Ramos-Quiroga

ADHD, attention deficit hyperactivity disorder; SUD, substance use disorders.

This Industry Interactive Discussion is open to healthcare professionals who attend the 36<sup>th</sup> ECNP Congress.

This Industry Interactive Discussion has been initiated, organized, and funded by Takeda Pharmaceuticals International AG.

Copyright 2023. Takeda Pharmaceutical Company Limited. All rights reserved. TAKEDA and  are registered trademarks of Takeda Pharmaceutical Company Limited, used under license.

C-APROM/SE/ELVS/0071 | Date of preparation: Aug 2023



infosweden@takeda.com  
www.takeda.se